Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) has appointed Accelerating Clinical Trials (ACT) to run its phase 2a cancer trial for POLB 001. The drug aims to cut dangerous immune reactions in patients on immunotherapy, with interim data expected in summer 2026. Read more
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) lowered 2025 revenue guidance to $2.5–3.5 million after US hospital funding cuts slowed sales. But its pipeline of customer quotes is over $21 million, and it remains on track for 2026 growth. Read more
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) expects to break even on cash flow by the end of 2025. Sales are climbing as new EU rules will require driver-monitoring systems in all cars from July 2026. Read more
Chariot Ltd (AIM:CHAR, OTC:OIGLF) has split into oil and gas and renewable power businesses, with $5.6 million in cash at half-year. It is advancing the Anchois gas project in Morocco and renewable ventures across South Africa, Zambia and Zimbabwe. Read more
Valereum PLC (AQSE:VLRM) has acquired 79.2 million GATE tokens for its treasury. The tokens will power its regulated tokenisation platform and act as the utility backbone of its marketplace. Read more
Vaultz Capital PLC (AQSE:V3TC) has appointed BitGo to safeguard its Bitcoin reserves. BitGo oversees $90 billion in assets and offers multi-signature security with insurance cover of up to $250 million. Read more
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.